
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
What information do ob/gyns need and where do they get it? The answers are in a recent survey.
Online and electronic media are of increasing interest to ob/gyns, according to the results of





